Contract notice
Section I: Contracting
authority
I.1) Name and addresses
NHS BLMK Clinical Commissioning Group
Capability House
Bedford
MK45 4HR
UK
Contact person: Samuel Naxton
E-mail: samuel.naxton@attain.co.uk
NUTS: UKH24
Internet address(es)
Main address: https://www.blmkccg.nhs.uk/
I.3) Communication
The procurement documents are available for unrestricted and full direct access, free of charge at:
https://attain.bravosolution.co.uk/web/login.html
Additional information can be obtained from the abovementioned address
Tenders or requests to participate must be sent electronically to:
https://attain.bravosolution.co.uk/web/login.html
Tenders or requests to participate must be sent to the abovementioned address
I.4) Type of the contracting authority
Body governed by public law
I.5) Main activity
Health
Section II: Object
II.1) Scope of the procurement
II.1.1) Title
Community Lipid Management Service
Reference number: ACE-0490-2021-BLMK
II.1.2) Main CPV code
85000000
II.1.3) Type of contract
Services
II.1.4) Short description
NHS BLMK CCG secured Pathway Transformation Funding (PTF) to support the adoption of a new lipid management pathway and the establishment of community lipid services and this EOI process seeks to identify and select a suitable provider to deliver the community lipid service. The purpose of the Community Lipid Service is to provide a consistent, evidence-based approach to lipid management across BLMK CCG. The Community Lipid Clinic will form part of a new pathway developed with key stakeholders across BLMK, in line with evidenced-based best practice. The service will be funded to provide clinical activity to optimise lipid management in populations at very high risk of CVD (as defined by the commissioner) and provide clinical assessment for familial hypercholesterolemia in people meeting appropriate clinical criteria (as defined by the commissioner), in line with locally developed evidence-based pathways. The Community Lipid Clinic will accept referrals of people meeting the relevant clinical criteria who are registered with a GP practice in Bedfordshire, Luton and Milton Keynes Integrated Care System.
II.1.5) Estimated total value
Value excluding VAT:
200 000.00
GBP
II.1.6) Information about lots
This contract is divided into lots:
No
II.2) Description
II.2.2) Additional CPV code(s)
85323000
II.2.3) Place of performance
NUTS code:
UKH24
Main site or place of performance:
Bedfordshire, Luton and Milton Keynes
II.2.4) Description of the procurement
The Community Lipid service will offer:
• A full assessment of people referred with CVD and/or FH and also uncontrolled hypercholesterolaemia or mixed dyslipidemia, including review of current and previous lipid lowering treatments, adherence with treatment regimes and any reasons for discontinuation.
• Pharmacological management and monitoring of effectiveness and tolerability in line with pathways agreed with the commissioner.
• Requesting of appropriate pathology tests at appropriate intervals through the relevant pathology system.
• Electronic prescription of relevant medications, in sufficient quantity to meet the requirements for uptitration between review contacts.
• Comprehensive documentation of each clinical contact in the shared clinical record on SystmOne.
• Support for self-management and education on the significance of managing cardiovascular risk factors, including cholesterol.
• Appropriate signposting to other services to support optimisation of health and wellbeing, including weight management, smoking cessation, alcohol support and talking therapies.
• Onward referral to specialist lipid services of patients with uncontrolled lipids despite maximum tolerated oral therapy, in line with criteria and pathways agreed with the commissioner
• Clinical assessment of people with clinical features suggestive of suspected FH (as defined by the commissioner), with onward referral as appropriate to specialist lipid services
• Clear treatment plans with appropriate patient-driven uptitration of therapy, timing of repeat lipid testing and scheduling of follow-up to allow maximal impact from each clinical contact.
II.2.5) Award criteria
Criteria below:
Quality criterion: Quality
/ Weighting: 100%
Cost criterion: Price
/ Weighting: 0%
II.2.6) Estimated value
Value excluding VAT:
200 000.00
GBP
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 12
This contract is subject to renewal: Yes
Description of renewals:
Option to extend for a further 12 months subject to funding, learning and benefits outcomes.
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
Yes
Description of options:
Option to extend contract for a further 12 months subject to funding, learning and benefits outcomes.
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Section IV: Procedure
IV.1) Description
IV.1.1) Type of procedure
Open procedure
IV.1.8) Information about Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement:
No
IV.2) Administrative information
IV.2.2) Time limit for receipt of tenders or requests to participate
Date:
01/09/2021
Local time: 12:00
IV.2.4) Languages in which tenders or requests to participate may be submitted
EN
IV.2.7) Conditions for opening of tenders
Date:
01/09/2021
Local time: 12:01
Section VI: Complementary information
VI.1) Information about recurrence
This is a recurrent procurement:
No
VI.3) Additional information
The Community Lipid Clinic will work with a range of partners to address the needs of the patients. These partners include (not an exhaustive list):
• General Practices
• Community service providers in BLMK ICS
• Acute trusts in BLMK ICS
• Public Health
• Lifestyle and wellbeing services
• Other Local Authority funded services
• Voluntary/Community/Third Sector providers
• Other services relevant to specific patient, family and/or carers needs e.g. interpreters
• Bedfordshire Luton and Milton Keynes Clinical Commissioning Group
• Bedfordshire Luton and Milton Keynes Integrated Care System
Discharge from the service will occur if:
• Treatment targets are achieved and lipid-lowering therapy is sufficiently tolerated to continue
• Maximal oral tolerated therapy has not achieved treatment targets
• The patient does not agree to optimisation of lipid-lowering therapy
• In the absence of tolerability issues or practical difficulties which may be overcome, there is suboptimal compliance with treatment plans which negates further intensification of therapy
• The patient meets criteria for onward referral to specialist lipid services
• The patient ceases to be registered with a General Practice in BLMK CCG / ICS
The service will also meet the following requirements:
• Effective quality assurance including clinical supervision and reflective practice
• Clear processes for collection and reporting of significant events, near misses and clinical incidents to the commissioner and demonstration of effective learning from these events
• Regular evaluation of the service
• Access to the relevant pathology systems for Luton, Bedfordshire and Milton Keynes
• Proficiency in use of SystmOne and integration with local primary care clinical records
• Provision of specified data to the commissioner at specified timepoints
• Use of appropriately trained and qualified workforce, with up-to-date mandatory training (including, but not limited to, Basic Life Support and Child and Adult Safeguarding Level 3)
• Access to translation services and other relevant measures to support equity
Contract Period: 01/11/2021 to 31/10/2022 (with option to extend once up to a further 12 months, subject to funding, learning and benefit outcomes). Maximum of a 24-month contract
Contract Value: £100,000 for 12 months.
Total Contract Value ££200,000
VI.4) Procedures for review
VI.4.1) Review body
High Court of Justice of England and Wales
Strand
London
WC2A 2LL
UK
VI.5) Date of dispatch of this notice
30/07/2021